Fused Cells, E.g., Hybridoma, Etc. Patents (Class 530/809)
-
Patent number: 5583005Abstract: The present invention provides novel monoclonal antibodies HE-22A, HE-35A, HE-39E, and HE-69B against human IgE, a mixture thereof, hybridomas producing the antibodies, and immunoassays of human IgE employing the antibodies, which are useful for clinical diagnosis of allergic diseases or parasitic infections.Type: GrantFiled: April 27, 1995Date of Patent: December 10, 1996Assignee: Shionogi & Co., Ltd.Inventors: Shinji Nishimura, Shigenori Harada
-
Patent number: 5573957Abstract: A monoclonal antibody having high affinity to human cardiac myoglobin, which has undergone a conformational change resulting from the binding of the molecule to another molecule is described. This monoclonal antibody can be used in a rapid format double antibody immunoassay system to identify blood, serum or plasma levels of cardiac myoglobin. Such an immunoassay system can be used for diagnosing and quantifying myocardial necrosis and infarction.Type: GrantFiled: September 28, 1994Date of Patent: November 12, 1996Assignee: Spectral Diagnostics, Inc.Inventors: Beatrice Cardone, George Jackowski
-
Patent number: 5532137Abstract: Monoclonal or polyclonal antibodies capable of recognizing at least one antigenic determinant located on the FR-900506 compound, are disclosed. FR-900506 isa compound having pharmacological activities such as immunosuppressive activity and antimicrobial activity, and has the following structure: ##STR1## Also disclosed are enzyme immunoassays for FR-900506 based on the antibodies of the invention and test kits for detection of FR-900506. A process for preparing a monoclonal antibody which selectively binds to FR-900506 is also disclosed.Type: GrantFiled: June 6, 1996Date of Patent: July 2, 1996Assignee: Fujisawa Pharmaceutical Co., Ltd.Inventors: Mineo Niwa, Kouichi Tamura, Tsutomu Kaizu, Masakazu Kobayashi
-
Patent number: 5466784Abstract: Hybridoma cell lines have been produced which produce and secrete monoclonal antibodies which bind salinomycin and are effective to detect salinomycin levels as low as about 0.174 to about 0.793 ng. These monoclonal antibodies may be used for the detection and quantitative determination of very low levels of salinomycin in samples, especially in animal tissue and feed material.Type: GrantFiled: June 23, 1993Date of Patent: November 14, 1995Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Larry H. Stanker, Marcel H. Elissalde, Jr., Ross C. Beier, Loyd D. Rowe, Jr., John R. DeLoach
-
Patent number: 5389530Abstract: The present invention relates to an improved method for the production of antibodies to tumor-associated gangliosides using ganglioside lactones. The resulting antibodies are useful in the detection and treatment of tumors containing gangliosides. The present invention also relates to methods of treatment of tumors by active immunization using ganglioside lactones.Type: GrantFiled: July 27, 1993Date of Patent: February 14, 1995Assignee: The Biomembrane InstituteInventor: Sen-itiroh Hakomori
-
Patent number: 5286647Abstract: Novel hybridomas, human monoclonal antibodies and their uses are provided. The antibodies distinguish a human neoplastic cell from a normal cell of the same tissue type. The monoclonal antibodies find use in therapy and diagnosis, both in vitro and in vivo.Type: GrantFiled: October 23, 1987Date of Patent: February 15, 1994Assignee: University of CaliforniaInventors: Harold H. Handley, Mark C. Glassy, Ideaki Hagiwara, Yoshihide Hagiwara
-
Patent number: 5248768Abstract: Glycopeptides of human cytomegalovirus have been isolated and purified. These glycopeptides and antibodies reactive with them are useful in diagnosis and therapy.Type: GrantFiled: June 26, 1991Date of Patent: September 28, 1993Assignee: The Children's Hospital, IncorporatedInventors: Nancy O. Lussenhop, Bruce E. Kari, Richard C. Gehrz
-
Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
Patent number: 5245015Abstract: The monoclonal antibodies (mAbs) of the invention bind to a neutralizing epitope on the gp120 glycoprotein of HIV-1. The binding seems to be conformation-dependent, in the sense that altering the conformation of gp120 (by deglycosylating the gp120, by reducing the cysteine bonds in the peptide backbone) will inhibit the binding. The mAbs of the invention are group specific and can neutralize different strains and different isolates of HIV-1. The binding of these mAbs to gp120 is enhanced by the binding of other antibodies to the principal neutralizing determinant (amino acid residue numbers 296-331) of gp120.Type: GrantFiled: April 26, 1991Date of Patent: September 14, 1993Assignee: Tanox Biosystems, Inc.Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun -
Patent number: 5223417Abstract: Disclosed herein is a method for transforming human B-cells preferably by infecting them with Epstein-Barr virus followed by transforming the Epstein Barr virus infected cells with an activated human ras gene. The transformed cells are useful for producing human monoclonal antibodies either without further manipulation or after fusion with antibody-secreting cells.Type: GrantFiled: November 8, 1991Date of Patent: June 29, 1993Assignee: New York UniversityInventors: Riccardo Dalla-Favera, Stephanie Seremetis
-
Patent number: 5223427Abstract: Murine hybridomas producing monoclonal antibodies capable of immunoreacting with huTFh and polypeptide analogs are described. Also contemplated are immunologic methods for detecting huTF heavy chain in body fluid, detecting thrombic events in vivo, isolating coagulation factor, and neutralizing VII/VIIa coagulation factor binding in vivo.Type: GrantFiled: March 9, 1988Date of Patent: June 29, 1993Assignee: The Scripps Research InstituteInventors: Thomas S. Edgington, James H. Morrissey
-
Patent number: 5217869Abstract: Screening methods to obtain suitable antibodies for use in immunoassays for analytes not ordinarily susceptible to detection by this means involves in vitro screening of panels of cells secreting a representative selection of antibodies. An application of this method also permits the preparation of specific mimotopes which mimic the immunological activity of the desired analyte, which mimotopes can then be used as competitors in the immunoassay or can be used to immunize subject mammals in order to improve the specificity and affinity of the antibodies. Methods to identify a particular analyte by its pattern of binding strength to a panel of related antibodies and to match an arbitrary analyte with an immunoreactive member of a panel of candidate antibodies are also disclosed.Type: GrantFiled: October 11, 1988Date of Patent: June 8, 1993Assignee: Terrapin Technologies, Inc.Inventor: Lawrence M. Kauvar
-
Patent number: 5208146Abstract: Murine monoclonal anti-idiotype antibodies raised against a human monoclonal anti-ganglioside antibody identified as L612. Both alpha and beta type anti-idiotype antibodies are disclosed which belong to the IgG1 class and contain kappa light chains. Two hybridoma cell lines which produced the monoclonal anti-idiotype antibodies are identified. The beta-type anti-idiotype antibodies are useful as an immunization agent to raise antibodies which are immunoreactive with tumors. The alpha-type anti-idiotype antibodies are useful as a probe for use in detecting human monoclonal antibodies bound to biopsied tumor tissues and to identify expression of ganglioside antigens on biopsied human tissues.Type: GrantFiled: November 5, 1990Date of Patent: May 4, 1993Assignee: The Regents of the University of CaliforniaInventor: Reiko F. Irie
-
Patent number: 5173293Abstract: An antigen/antibody complex is described wherein the antibody functions as an adjuvant. The antibody comprises an anti-lymphocyte antibody. The antigen comprises a hapten, peptide, protein, carbohydrate, virus, bacterium, parasite or other whole microorganism. The complex of antigen coupled to antibody may be used in immunizing a higher animal against an antigen.Type: GrantFiled: February 23, 1989Date of Patent: December 22, 1992Assignee: Becton Dickinson and CompanyInventors: Sherree L. Friend, Vernon T. Oi
-
Patent number: 5171666Abstract: The present invention relates to a novel tumor-associated antigen that is a cell-surface glycoprotein having a molecular weight in the range of 110,000-140,000 daltons that is present in a variety of carcinomas, including squamous cell carcinomas and adenocarcinomas. The invention also comprises antibodies reactive with the antigen, hybridoma cell lines that produce the antibodies of the invention, and methods for using the antibodies in the diagnosis and treatment of cancer.Type: GrantFiled: October 19, 1988Date of Patent: December 15, 1992Assignee: Eli Lilly and CompanyInventors: Magda C. Gutowski, David A. Johnson
-
Patent number: 5160723Abstract: This invention provides a method of imaging a colorectal carcinoma lesion in a human patient which comprises administering to the patient a monoclonal antibody capable of binding to a cell surface antigen associated with the coloretal carcinoma lesion and which is labeled with an imaging agent under conditions so as to form a complex between the monoclonal antibody and the cell surface antigen, imaging any complex so formed, and thereby imaging the colorectal carcinoma lesion.This invention also provides a monoclonal antibody designated AS 33 (ATCC Accession No. HB 8779) and the hybridoma which produces it.Type: GrantFiled: March 18, 1991Date of Patent: November 3, 1992Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Sydney Welt, Chaitanya R. Divgi, Samual Yeh, Lloyd J. Old, Herbert F. Oettgen, Francisco X. Real, Junichi Sakamoto
-
Patent number: 5158870Abstract: Monoclonal antibodies binding Mycoplasma genitalium more strongly than Mycoplasma pneumoniae, Mycoplasma hominis, Mycoplasma orale, Mycoplasma salivarium and Acholeplasm laidlawii are described herein. These monoclonal antibodies are utilized in immunoassays directed toward the detection of M. genitalium infections. Hybridomas producing the above-described monoclonal antibodies have been created and isolated. These monoclonal antibodies are directed toward M. genitalium antigens. Certain antibodies bind protein antigens, while others bind lipid antigens. In one case a particular antibody apparently has binding affinity for both protein and lipid antigens of M. genitalium.Type: GrantFiled: February 16, 1990Date of Patent: October 27, 1992Assignee: Board of Regents, The University of Texas SystemInventors: Joel B. Baseman, Janice Morrison-Plummer
-
Patent number: 5153118Abstract: Monoclonal antibodies having binding specificity to human prostate tumor-associated antigens but not to prostate-specific antigen (PSA) or prostatic acid phosphatase (PAP); and methods of diagnosis and treatment employing the same.Type: GrantFiled: October 25, 1988Date of Patent: October 6, 1992Assignee: Eastern Virginia Medical AuthorityInventors: George L. Wright, Jr., James J. Starling
-
Patent number: 5144010Abstract: This invention provides an auto-anti-idiotypic method for producing a monoclonal anti-idiotypic antibody. The method involves contacting lymphoid cells of an animal under suitable conditions with an effective antibody-raising amount of an antigen, collecting the lymphoid cells from the animal at a suitable time after the contacting and fusing the collected lymphoid cells with appropriate myeloma cells to produce a series of hybridoma cells each of which produces a monoclonal antibody. The method further involves screening, under suitable conditions, the series of hybridoma cells so produced to identify those which secrete a monoclonal antibody capable of binding to an antibody directed to the antigen, or to a receptor where the antigen is a ligand to the receptor, separately culturing a hybridoma cell so identified in an appropriate medium, and separately recovering under suitable conditions the monoclonal anti-idiotypic antibody produced by the hybridoma cell.Type: GrantFiled: November 18, 1989Date of Patent: September 1, 1992Assignee: The Trustees of Columbia University in the City of New YorkInventors: Bernard F. Erlanger, William L. Cleveland
-
Patent number: 5143726Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.Type: GrantFiled: November 20, 1989Date of Patent: September 1, 1992Assignee: The Scripps Research InstituteInventors: George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
-
Patent number: 5120642Abstract: A monoclonal antibody which binds preferentially to a subset of the human CD4+ lymphocyte population whereby to positively and precisely distinguish between helper-inducer and suppressor-inducer cells in the CD4+ cell population. The monoclonal antibody recognizes a novel antigen on the CD4+ lymphocytes by means of which it can bind CD4+ cells which express the antigen on the surface of CD4+ cells. The CD4+ subset cell population to which this antibody preferentially binds is the CD4+ helper-inducer population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and possible therapeutic applications thereof to be realized. The monoclonal antibody also reacts with CD8 cells, B cells and macrophages.Type: GrantFiled: November 28, 1989Date of Patent: June 9, 1992Assignee: Coulter CorporationInventors: Stuart F. Schlossman, Chikao Morimoto
-
Patent number: 5118611Abstract: Novel adenocarcinoma binding human monoclonal antibody binds preferentially with ADCA antigens and is useful in diagnostic and imaging methods for identifying and locating adenocarcinoma cells, and in therapeutic methods to reduce the reproduction of adenocarcinoma cells. The novel ADCA antigen is useful in methods for diagnosing the presence of adenocarcinoma. The antigen, antibodies, hybridoma, reagents, therapeutic agents and methods of use are aspects of the invention.Type: GrantFiled: October 3, 1988Date of Patent: June 2, 1992Assignee: Adeza Biomedical CorporationInventors: Lloyd H. Smith, Nelson N. H. Teng
-
Patent number: 5112738Abstract: Histamine derivatives, immunogen conjugates comprising histamine or said histamine derivatives coupled to immunogenic carrier materials and antibodies prepared against such immunogen conjugates are disclosed. Such antibodies are useful in immunoassays for determining histamine release in biological fluids.Type: GrantFiled: October 28, 1988Date of Patent: May 12, 1992Assignee: Miles Inc.Inventors: Robert T. Buckler, Frank A. Dailey, John A. Ficalora, John J. Gavin, Gregory A. Plunkett
-
Patent number: 5110738Abstract: The present invention is concerned with a monoclonal antibody capable of preferentially recognizing arteriosclerotic lesions and prepared from a hybridoma obtained by fusing myeloma cells and cells capable of producing antibodies against arteriosclerotic lesions, such as spleen cells, peripheral lymphocyte of thymus and peripheral vascular cells, the antibody can be to use as an agent for detecting the presence of arteriosclerotic lesions and for treating arteriosclerosis.Type: GrantFiled: December 14, 1987Date of Patent: May 5, 1992Assignee: Research Development Corporation of JapanInventors: Tatsuya Takano, Ryoichi Hashida, Keiji Nakagami, Junji Kimura
-
Patent number: 5101017Abstract: A monoclonal antibody which identifies the human blood group Duffy (ab) is provided. Such monoclonal antibody blocks the penetration of P. vivax malaria parasite into human red blood cells by virtue of effective blocking of the target molecule of the P. vivax malaria parasite. Such monoclonal antibody has a combining site having the same stereochemistry as the ligand site on P. vivax, and elicits anti-idiotypic antibodies that react with the parasite.Type: GrantFiled: April 6, 1987Date of Patent: March 31, 1992Assignee: New York Blood Center, Inc.Inventors: Pablo Rubinstein, Margaret Nichols
-
Patent number: 5096810Abstract: Monoclonal antibodies are described which are potent reagents for the immunologic definition of hairy leukemic cells.S-HCL 1 is a pan-B cell marker with markedly increased staining on hairy cells versus normal B-lymphocytes. It also stains with a variety of B-cell leukemias and lymphomas, but is not crossreactive with any other cell type in man. With these features, it is also a useful reagent for the detection of human B-lymphocytes.S-HCL-3 monoclonal antibody recognizes an antigen present on entirely different cell lineages, namely macrophages of almost all tissues and polymorphonuclear cells. This antigen is not expressed on any other malignant lymphocytes except hairy cells. Moreover, this antigen is not found on other non-Hodgkin lymphomas which may resemble hairy cell leukemia. Accordingly, b-HCl-3 is useful in the diagnosis of hairy cell leukemic.Type: GrantFiled: March 11, 1986Date of Patent: March 17, 1992Assignee: Sloan-Kettering Institute For Cancer ResearchInventors: Roland Schwarting, Robert Evans
-
Patent number: 5094941Abstract: Monoclonal antibodies (MAbs) capable of binding to native PDGF, and MAbs capable of specifically binding to the PDGF-AA, PDGF-BB and PDGF-AB isoforms are disclosed. The subject MAbs may be used in the detection or purification of native PDGF or selected PGDF isoforms. In addition, the MAbs may be labeled with an imaging agent and used for in vivo diagnostic purposes, or combined with a pharmaceutically acceptable carrier or diluent for use within wound healing compositions.Type: GrantFiled: December 31, 1987Date of Patent: March 10, 1992Assignee: ZymoGenetics, Inc.Inventor: Charles E. Hart
-
Patent number: 5085984Abstract: Novel Fc receptors, denoted type VI, are disclosed as reacting with rat immunoglobulins with a reasonable affinity. These receptors, or the microorganisms which produce them, are useful in immunoassays.Type: GrantFiled: April 23, 1990Date of Patent: February 4, 1992Assignee: University of Florida Research Foundation, Inc.Inventors: Michael D. P. Boyle, Kathleen J. Reis
-
Patent number: 5077391Abstract: Immunoglobulin M is purified by absorption upon an insoluble matrix material having chemically bound thereon the protein C1q. The matrix is washed and purified immunoglobulin M is then released from the matrix.Type: GrantFiled: December 1, 1989Date of Patent: December 31, 1991Inventors: Robert L. Raison, Simon B. Easterbrook-Smith, Andrew G. Nethery
-
Patent number: 5071744Abstract: Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.Type: GrantFiled: October 9, 1990Date of Patent: December 10, 1991Assignee: Boehringer Mannheim GmbHInventors: Kurt Naujoks, Karl Wulff, Martin Gerber
-
Patent number: 5071962Abstract: The present invention relates to novel polypeptides comprising a unique "chlamydial-specific" primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokaryotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.Type: GrantFiled: May 31, 1990Date of Patent: December 10, 1991Assignee: The United State of America as represented by the Department of Health and Human ServicesInventors: Richard P. Morrison, Harlan D. Caldwell
-
Patent number: 5070013Abstract: Monoclonal antibodies and compositions thereof are provided for detecting, measuring, and immunopurifying human GM-CSF.Type: GrantFiled: May 31, 1988Date of Patent: December 3, 1991Assignee: Schering CorporationInventors: John S. Abrams, Robert E. Van Dyke
-
Patent number: 5066581Abstract: This invention provides a purified new differentiation antigen, designated NDA.sub.3, associated with the growth and proliferation of activated B lymphocytes and characterized by a molecular weight of about 36,000 daltons.The invention also provides an antibody capable of specifically forming a complex with purified NDA.sub.3. Another aspect of the invention provides a hybridoma which produces a monoclonal antibody that specifically recognizes the isolated NDA.sub.3.The invention also pertains to a method for detecting B cells or helper T cells, each of which has a B cell growth factor receptor, which comprises contacting a sample which contains B cells or helper T cells with substances capable of forming complexes with the B cell growth factor receptors so as to form cellular complexes between the substances and the B cell growth factor receptors, and detecting such cellular complexes.Type: GrantFiled: February 5, 1987Date of Patent: November 19, 1991Assignee: The Trustees of Columbia University in the City of New YorkInventors: Nicole Suciu-Foca, Donald W. King
-
Patent number: 5059523Abstract: This invention provides a method of identifying mesenchymal tissues as normal, proliferatively active or malignant. This invention also provides a method of distinguishing subsets of sarcomas with distinctive antigenic phenotypes. This invention also provides a method of diagnosing mesenchymal tumors. Finally, this invention provides a monoclonal antibody designated G171 and the hybridoma cell line producing said monoclonal antibody (ATCC No. HB9254).Type: GrantFiled: May 2, 1988Date of Patent: October 22, 1991Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Wolfgang J. Rettig, Pilar Garin-Chesa, H. Richard Beresford, Herbert F. Oettgen, Myron R. Melamed, Lloyd J. Old
-
Patent number: 5055558Abstract: A method for the selective extraction of beta-lactoglobulin and other proteins from whey or milk by means of subunit exchange chromatography and for the deproteinization of whey by subsequent chromatography on an ion exchange resin.Type: GrantFiled: March 25, 1988Date of Patent: October 8, 1991Assignee: Consiglio Nazionale Della RicercheInventors: Emilia Chiancone, Maurizio Gattoni
-
Patent number: 5053336Abstract: Monoclonal antibodies are described which have specific affinities for halogenated nucleoside analogs and are preferentially selective for one particular halogen. Such antibodies, when incorporated into immunochemical reagents, may be used to identify and independently quantify the cell division character of more than one population or subpopulation in flow cytometric measurements. Independent assessment of division activity in cell sub-populations facilitates selection of appropriate time and dose for administration of anti-proliferative agents. The hybridomas which secrete halogen selective antibodies and the method of making them are described.Type: GrantFiled: July 17, 1989Date of Patent: October 1, 1991Assignee: Regents of the University of CaliforniaInventors: Martin Vanderlaan, Bruce E. Watkins, Larry H. Stanker
-
Patent number: 5053327Abstract: Hybrid cell lines (hybridomas) which produce and secrete high affinity monoclonal antibodies specific for Bowman-Birk inhibitor (BBI) are described. High affinity antibodies to BBI are described that have one or more of the following additional characteristics: (1) they are specific to the active form of BBI, that is, they react and bind with undenatured BBI, but do not bind with BBI which has been denatured by heat or disulfide exchange; (2) they do not react and bind with KTI; (3) they distinguish classical BBI from other BBI's including lima bean protease inhibitor; and (4) they bind BBI-protease complex, e.g., BBI-chymotrypsin. Immunoassay methods using the monoclonal antibodies to analyze BBI specifically in plant, animal or human tissue or fluid or foodstuffs and techniques for immunoaffinity binding of BBI are described.Type: GrantFiled: September 20, 1988Date of Patent: October 1, 1991Assignee: The United States of America as represented by the Secretary of AgricultureInventors: David L. Brandon, Anne H. Bates, Mendel Friedman
-
Patent number: 5051355Abstract: An anti-human gastric cancer monoclonal antibody, AMC-462, which belongs to the class IgG.sub.1, reacts with human digestive system cancer, and recognizes sialylated glycoproteins or glycolipids as the antigen is disclosed. It is effective for diagnosis of digestive system cancer, especially pancreatic cancer.Type: GrantFiled: December 6, 1989Date of Patent: September 24, 1991Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Hajime Yoshida, Nobuo Hanai, Akiko Furuya
-
Patent number: 5043263Abstract: The present invention is directed to monoclonal antibodies, and hybridomas which produce them, which are reactive with a highly conserved epitope present on potyviruses and insignificantly reactive with other plant viruses, as well methods of using these monoclonal antibodies to detect potyviruses.Type: GrantFiled: May 24, 1990Date of Patent: August 27, 1991Inventors: John Hammond, Ramon L. Jordan, Jr.
-
Patent number: 5043340Abstract: Derivatives of 4-desacetyl VLB C-3 carboxhydrazide, active anti-tumor agents and useful as intermediates for active anti-tumor conjugates.Type: GrantFiled: April 3, 1990Date of Patent: August 27, 1991Assignee: Eli Lilly and CompanyInventor: George J. Cullinan
-
Patent number: 5032521Abstract: Hybridomas are provided which secrete an IgG1 or IgG2 monoclonal antibody which binds to an epitope on an antigen, which occurs in the plasma membrane of MCF-7 cells and has a molecular weight of 22 kD. The epitope of the antibodies is exposed on the extracellular side of the plasma membrane of the MCF-7 cells. The monoclonal antibodies, which react generally with human mammary carcinoma cells, but with few non-mammary cancer cells, are useful diagnostically and therapeutically.Type: GrantFiled: March 23, 1987Date of Patent: July 16, 1991Assignee: The Salk Institute for Biological StudiesInventors: Christine A. White, Renato Dulbecco, William R. Allen
-
Patent number: 5019511Abstract: Monoclonal antibodies are disclosed that react with an antigenic polypeptide having a molecular weight of approximately 45,000 that is expressed in the cell membrane of P. falciparun-infected erythrocytes. The antibodies were raised using the Honduras CDC isolate, and can be used for diagnostic purposes. The hybridoma producing the monoclonal antibodies is also disclosed.Type: GrantFiled: April 14, 1988Date of Patent: May 28, 1991Inventors: Robert T. Reese, Harold A. Stanley
-
Patent number: 5008198Abstract: The invention comprises antigenic glycoproteins substantially similar to antigenic glycoproteins present on the surface of the merozoite form of Plasmodium falciparum, including glycoproteins of molecular weights of about 56,000 present in the Geneva and FVO isolates and about 50,000 that is present in the Honduras I/CDC, Indochina 1, Kenya and Tanzania I isolates. The invention also comprises monoclonal antibodies 4-8-5D (HB 8938) which bind to the 56,000 glycoprotein of the invention, a hybridoma cell line that is capable of producing these monoclonal antibodies, and vaccines and vaccine compositions comprising these glycoproteins or epitopes substantially similar to or cross reactive with these glycoproteins or genes or gene fragments encoding such epitopes.Type: GrantFiled: May 30, 1989Date of Patent: April 16, 1991Assignee: Scripps Clinic and Research FoundationInventors: Robert T. Reese, Harold A. Stanley
-
Patent number: 5004694Abstract: Novel monoclonal antibodies specific to Trichomonas vaginalis, having complement--fixing ability and lysing Trichomonas vaginalis in the presence of complement are disclosed and may be used in therapy and diagnosis of trichomoniasis. Hybridomas producing and compositions comprising these antibodies are also disclosed.Type: GrantFiled: September 4, 1987Date of Patent: April 2, 1991Assignee: Interpharm Laboratories Ltd.Inventors: Neomi Moay, Enrica Draghi
-
Patent number: 5002869Abstract: A monoclonal antibody which binds preferentially to a subset of the human CD8 lymphocyte population whereby to positively and precisely distinguish between cytotoxic effector and supressor effector cells in the CD8 cell population. The monoclonal antibody recognizes a novel epitope of LFA-1 antigen by means of which it can bind CD8 cells which express the eptope on a surface antigen thereof. The CD8 subset cell population to which this anitbody binds preferentially is the CD8 cytotoxic effector population. This selectivity of the monoclonal antibody enables cell sorting, diagnostic and positive therapeutic applications thereof to be utilized.Type: GrantFiled: November 2, 1987Date of Patent: March 26, 1991Assignee: Dana-Farber Cancer InstituteInventors: Stuart F. Schlossman, Chikao Morimoto
-
Patent number: 5001225Abstract: A continuous hybridoma cell line, designated 7H8, which secretes a monoclonal antibody (MAb 7H8) of the IgM class and which binds to a protein present in species of the genus Plasmodium. MAb 7H8 also recognizes an antigen (antigen Pf93) unique to P. falciparum. Methods of isolating the substantially pure antigen using the antibody of the present invention are disclosed. MAb 7H8 is well suited for use in immunometric assays. Preferred is a two-sited assay developed with MAb 7H8. Anti-idiotypic and anti anti-idiotypic antibodies to MAb 7H8 are disclosed. The antibodies and antigens of the present invention are useful for immunodiagnostic and immunotherapeutic treatment of malarial diseases of man and animals.Type: GrantFiled: December 8, 1986Date of Patent: March 19, 1991Assignee: Georgetown UniversityInventor: Diane W. Taylor
-
Patent number: 4997764Abstract: Disclosed herein is a method for transforming human B-cells by infecting them with Epstein Barr virus and transfecting the Epstein Barr virus infected cells with an activated human c-myc gene. The transformed cells are useful for producing human monoclonal antibodies.Type: GrantFiled: April 23, 1987Date of Patent: March 5, 1991Assignee: New York UniversityInventor: Ricardo Dalla Favera
-
Patent number: 4990454Abstract: A monoclonal antibody specifically reactive to a human adenocarcinoma cell, which is obtainable by cultivating a fused cell obtained by fusing a mammalian animal cell, immunized with a human adenocarcinoma cell, with a myeloma cell.Type: GrantFiled: January 12, 1990Date of Patent: February 5, 1991Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Akira Yachi, Kohzoh Imai, Takao Endo, Yuji Hinoda, Takafumi Yamashita, Hideo Fujita
-
Patent number: 4990326Abstract: Use of labeled monoclonal antibody 50 H.19 to detect the location and concentration of blood platelets in a host is disclosed. MAb 50 H.19 labeled with a label which can be detected from without the host (e.g. a radiolabel or NMR-label) is intravenously injected to immunoreact with platelets in vivo or is first immunoreacted in vitro with platelets, which are then intravenously injected into the host. By means of the labeled MAb 50 H.19 bound platelets it is possible to detect and locate thrombi, emboli, atherosclerotic obstructions, bacterial endocarditis and to do spleen imaging. In another embodiment of the invention, the MAb 50 H.19 is bound to an enzymatic thrombolytic agent and injected intravenously to permit the therapeutic application of the agent directly to thrombi.Type: GrantFiled: March 15, 1988Date of Patent: February 5, 1991Assignee: Summa Medical CorporationInventors: Antoine A. Noujaim, Bryan M. Longenecker
-
Patent number: 4981961Abstract: A novel class of compounds, methods for the preparation thereof and the use thereof in chromatographic methods for binding various biologically active materials non-covalently are disclosed. The class of compounds comprises the reaction product of a polymeric gel with a pyridine base, such as 4-dimethylaminopyridine (DMAP), and a halogen-substituted pyridine, such as 3,5-dichloro-2,4,6-trifluoropyridine (DCTFP), which reaction product may in turn be optionally reacted with hydroxyl ions or specified low-molecular-weight compounds. These compounds are capable of selectively and efficiently binding proteins and other organic materials of interest non-covalently to a degree comparable or superior to the heretofore preferred natural affinity ligands, such as Protein A gels. The novel compounds find particular utility in purification and recovery of proteins such as serum albumin and immunoglobulins of various classes from crude sources, such as diluted serum samples from various species.Type: GrantFiled: September 8, 1989Date of Patent: January 1, 1991Assignee: BioProbe International, Inc.Inventor: That T. Ngo
-
Patent number: RE33653Abstract: Muteins of biologically active proteins such as IFN-.beta. and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect intramolecular disulfide bridge formation. These muteins are made via bacterial expression of mutant genes that encode the muteins that have been synthesized from the genes for the parent proteins by oligonucleotide-directed mutagenesis.Type: GrantFiled: July 26, 1989Date of Patent: July 30, 1991Assignee: Cetus CorporationInventors: David F. Mark, Leo S. Lin, Shi-da Y. Lu